Hjem › Diffust stort B-cellelymfom › Tennessee › Nashville
Kliniske studier for Diffust stort B-cellelymfom i Nashville, TN
15 studier for Diffust stort B-cellelymfom søker deltakere på steder i og rundt Nashville (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
RekruttererFase 2
- Vanderbilt University Medical Center, Nashville
Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma
RekruttererFase 2
- Vanderbilt University/Ingram Cancer Center, Nashville
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RekruttererFase 1/2
- Tennessee Oncology, Pllc Nashville, Nashville
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
RekruttererFase 1/2
- SCRI Oncology Partners ( Site 0100), Nashville
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
RekruttererFase 2
- SCRI Oncology Partners ( Site 7002), Nashville
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
RekruttererFase 1
- Sarah Cannon Research Institute, Nashville
- Vanderbilt University Medical Center, Nashville
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RekruttererFase 1
- SCRI Oncology Partners, Nashville
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
RekruttererFase 1
- Scri Oncology Partners, Nashville
- Vanderbilt Medical Center, Nashville
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
RekruttererFase 2
- Tennessee Oncology, Nashville
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
RekruttererFase 1/2
- Sarah Cannon Research Institute, Nashville
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
RekruttererFase 1/2
- Vanderbilt University Medical Center, Nashville
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
RekruttererFase 1/2
- TriStar BMT, Nashville
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
RekruttererFase 3
- SCRI Oncology Partners, Nashville
DALY II USA/ MB-CART2019.1 for DLBCL
RekruttererFase 2
- SCRI Oncology Partners, Nashville
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
RekruttererFase 1
- Tennessee Oncology, Nashville
Diffust stort B-cellelymfom-studier i andre byer
- New York City, NY21 studier
- Baldwin Park, CA19 studier
- Chicago, IL18 studier
- Houston, TX17 studier
- Los Angeles, CA17 studier
- Boston, MA16 studier
- Milwaukee, WI16 studier
- Portland, OR15 studier
- Philadelphia, PA15 studier
- Durham, NC14 studier
- Dallas, TX13 studier
- Seattle, WA12 studier
Andre studier i Nashville
- Ikke-småcellet lungekreft97 studier
- Brystkreft80 studier
- Metastatisk kreft70 studier
- Kolorektal kreft69 studier
- Kreft (alle typer)65 studier
- Eggstokkreft49 studier
- Prostatakreft42 studier
- Lungekreft40 studier
- Plateepitelcancer i hode og hals39 studier
- Pankreaskreft39 studier
- Endometriekreft38 studier
- Melanom33 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.